FDA Clarifies the Paperwork Behind Tomorrow's Supplement Ingredients
Published Date: 10/20/2026
Notice
Summary
The FDA just released clear, easy-to-follow guidance for companies making new dietary ingredients (NDIs) and supplements. This helps manufacturers know exactly what safety and identity info to include when they notify the FDA about their products. If you’re in the supplement business, this means smoother submissions and fewer headaches starting now—so get ready to update your paperwork and stay compliant!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Final FDA NDI Guidance Issued
On October 20, 2026, the FDA issued a final guidance giving manufacturers and distributors recommendations about what identity and safety information to include in New Dietary Ingredient Notifications (NDINs), including what types of studies to submit and when additional evidence of safety should be provided. The guidance also notes that the information collections in 21 CFR 190.6 included in the guidance are approved under OMB control number 0910-0330.
Single 'Safety Narrative' Replaces Multiple Documents
The FDA eliminated references to a separate "comprehensive safety profile" and instead recommends use of a single "safety narrative" for all NDINs to reduce the burden of submitting separate safety documents. This change is part of the final guidance announced October 20, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21452, Certain Linear Hydraulic Cylinders and Parts Thereof From the People's Republic of China, India, and Mexico: Postponement of Preliminary Determinations in the Countervailing Duty Investigations
The U.S. is investigating certain hydraulic cylinders from China, India, and Mexico to see if unfair government help is involved. The first big decision on this is delayed from November 12 to February 11, 2027, giving everyone more time to gather info. This delay could affect import costs and trade rules for companies dealing with these parts.
Next: 2026-21454, Agency Information Collection Activity: Application for Assumption Approval and/or Release From Personal Liability to the Government on a Home Loan
Veterans selling homes with VA-backed loans can apply to transfer their loan responsibility to buyers using a special form. The VA is updating this form because more people are using it, thanks to low-interest loans being popular now. If you want to comment on these changes, do it by November 19, 2026—no cost changes, just more paperwork to handle more requests.